PharmaCyte Biotech, Inc. - Common Stock (NQ:PMCB)

0.6300 UNCHANGED

Streaming Delayed Price Updated: 4:00 PM EST, Nov 20, 2025 Add to My Watchlist

Price and Volume

Volume	0
Open	0.6300
Bid (Size)	0.4868 (300)
Ask (Size)	0.8000 (100)
Prev. Close	0.6300
Today's Range	0.6300 - 0.6300
52wk Range	0.6300 - 1.900
Shares Outstanding	6,795,779
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

PharmaCyte Biotech, Inc. Increases Stake in TNF Pharmaceuticals Around Recent License for Breakthrough Light Speed Computing Platform for Use in Cryptocurrency Applications

September 02, 2025

From PharmaCyte Biotech, Inc.

Via Business Wire

PharmaCyte Biotech, Inc. Announces Closing of $7 Million Financing

August 20, 2025

From PharmaCyte Biotech, Inc.

Via Business Wire

Performance

YTD	-61.6%	-61.6%
1 Month	-35.6%	-35.6%
3 Month	-34.4%	-34.4%
6 Month	-38.2%	-38.2%
1 Year	-63.4%	-63.4%

More News

12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗

August 19, 2025

Via Benzinga

PMCB Stock Earnings: PharmaCyte Biotech Reported Results for Q3 2024 ↗

March 19, 2024

Via InvestorPlace

PharmaCyte Biotech, Inc. Announces $7 Million Capital Raise Led by Existing Investors

August 18, 2025

From PharmaCyte Biotech, Inc.

Via Business Wire

12 Health Care Stocks Moving In Tuesday's After-Market Session ↗

May 27, 2025

Via Benzinga

PharmaCyte Biotech Makes $7 Million Strategic Investment in MyMD, A Biopharmaceutical Company Focused on Inflammatory Disease

May 21, 2024

From PharmaCyte Biotech, Inc.

Via Business Wire

PMCB Stock Earnings: PharmaCyte Biotech Reported Results for Q2 2024 ↗

December 18, 2023

Via InvestorPlace

PharmaCyte Biotech Acquires $5 Million Stake in Emerging Women’s Health Innovator Femasys, Inc.

November 15, 2023

From PharmaCyte Biotech, Inc.

Via Business Wire

Femasys Inc. Secures Additional Financing with Strategic Investment from Investors led by PharmaCyte Biotech

November 15, 2023

From Femasys Inc.

Via GlobeNewswire

PharmaCyte Biotech Provides Corporate Update on Cell-in-a-Box Technology

October 31, 2023

From PharmaCyte Biotech, Inc.

Via Business Wire

Stocks That Hit 52-Week Lows On Tuesday ↗

September 26, 2023

Via Benzinga

PharmaCyte Biotech Announces Final Results of Tender Offer

June 15, 2023

From PharmaCyte Biotech, Inc.

Via Business Wire

12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗

May 11, 2023

Via Benzinga

PharmaCyte Biotech Announces Cash Tender Offer for up to 7,750,000 Shares at $3.25 Per Share

May 11, 2023

From PharmaCyte Biotech, Inc.

Via Business Wire

PharmaCyte Biotech to Implement Second $10-Million Share Repurchase Plan

February 02, 2023

From PharmaCyte Biotech, Inc.

Via Business Wire

PharmaCyte Biotech Reaches Cooperation Agreement with Iroquois Capital

August 15, 2022

From PharmaCyte Biotech, Inc.

Via Business Wire

PharmaCyte Biotech Rebukes Iroquois’ Commencement of Consent Solicitation

July 28, 2022

From PharmaCyte Biotech, Inc.

Via Business Wire

PharmaCyte Biotech Commences First Phase of Two-Phase Pig Study

July 21, 2022

From PharmaCyte Biotech, Inc.

Via Business Wire

PharmaCyte Biotech Reports Positive Interim Results in Malignant Ascites Mouse Model Study

July 19, 2022

From PharmaCyte Biotech, Inc.

Via Business Wire

PharmaCyte Biotech Announces Preliminary Unaudited Financial Results for Fiscal Year 2022

July 11, 2022

From PharmaCyte Biotech, Inc.

Via Business Wire

PharmaCyte Biotech Announces Additional Quality Control Assay and Confirms Stability of CypCap Cells

July 05, 2022

From PharmaCyte Biotech, Inc.

Via Business Wire

PharmaCyte Biotech Issues Follow-Up Response to Iroquois Capital’s Second Letter on June 9 and Reiterates Commitment to Increasing Shareholder Value

June 15, 2022

From PharmaCyte Biotech, Inc.

Via Business Wire

PharmaCyte Biotech to Attend 2022 BIO International Convention in San Diego

June 13, 2022

From PharmaCyte Biotech, Inc.

Via Business Wire

PharmaCyte Biotech Issues Response to Iroquois Capital Letter and Announces Additional Steps to Increase Shareholder Value

June 08, 2022

From PharmaCyte Biotech

Via Business Wire

Frequently Asked Questions

Is PharmaCyte Biotech, Inc. - Common Stock publicly traded?

Yes, PharmaCyte Biotech, Inc. - Common Stock is publicly traded.

What exchange does PharmaCyte Biotech, Inc. - Common Stock trade on?

PharmaCyte Biotech, Inc. - Common Stock trades on the Nasdaq Stock Market

What is the ticker symbol for PharmaCyte Biotech, Inc. - Common Stock?

The ticker symbol for PharmaCyte Biotech, Inc. - Common Stock is PMCB on the Nasdaq Stock Market

What is the current price of PharmaCyte Biotech, Inc. - Common Stock?

The current price of PharmaCyte Biotech, Inc. - Common Stock is 0.6300

When was PharmaCyte Biotech, Inc. - Common Stock last traded?

The last trade of PharmaCyte Biotech, Inc. - Common Stock was at 11/20/25 04:00 PM ET

What is the market capitalization of PharmaCyte Biotech, Inc. - Common Stock?

The market capitalization of PharmaCyte Biotech, Inc. - Common Stock is 4.28M

How many shares of PharmaCyte Biotech, Inc. - Common Stock are outstanding?

PharmaCyte Biotech, Inc. - Common Stock has 4M shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.